CRIS Current Research Information System

RODA, ENRICO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.821
AS - Asia 6.525
EU - Europa 4.786
AF - Africa 350
SA - Sud America 292
Continente sconosciuto - Info sul continente non disponibili 250
OC - Oceania 6
Totale 19.030
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.731
VN - Vietnam 2.174
SG - Singapore 1.648
CN - Cina 1.547
GB - Regno Unito 1.274
IT - Italia 609
SE - Svezia 590
DE - Germania 573
UA - Ucraina 415
HK - Hong Kong 355
FR - Francia 324
RU - Federazione Russa 270
IN - India 265
IE - Irlanda 193
BR - Brasile 189
NL - Olanda 114
JP - Giappone 108
KR - Corea 103
EE - Estonia 93
CI - Costa d'Avorio 92
BD - Bangladesh 91
ZA - Sudafrica 91
CH - Svizzera 74
FI - Finlandia 73
TG - Togo 59
CA - Canada 49
SC - Seychelles 47
PH - Filippine 39
AR - Argentina 36
JO - Giordania 36
GR - Grecia 34
BG - Bulgaria 31
NG - Nigeria 31
TH - Thailandia 31
BE - Belgio 30
PL - Polonia 27
TR - Turchia 24
EC - Ecuador 19
IR - Iran 19
TW - Taiwan 18
MX - Messico 16
ES - Italia 14
CL - Cile 12
AT - Austria 11
CO - Colombia 11
PK - Pakistan 11
ID - Indonesia 10
JM - Giamaica 10
LT - Lituania 9
VE - Venezuela 9
ET - Etiopia 8
LB - Libano 8
IQ - Iraq 7
CZ - Repubblica Ceca 6
PE - Perù 6
PY - Paraguay 6
AO - Angola 5
HR - Croazia 5
IL - Israele 5
MY - Malesia 5
SA - Arabia Saudita 5
AU - Australia 4
CR - Costa Rica 4
DK - Danimarca 4
EG - Egitto 4
UZ - Uzbekistan 4
MA - Marocco 3
NI - Nicaragua 3
PT - Portogallo 3
TN - Tunisia 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
AZ - Azerbaigian 2
BB - Barbados 2
DZ - Algeria 2
EU - Europa 2
HU - Ungheria 2
KE - Kenya 2
NZ - Nuova Zelanda 2
RO - Romania 2
SY - Repubblica araba siriana 2
UY - Uruguay 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BO - Bolivia 1
CG - Congo 1
DM - Dominica 1
GE - Georgia 1
GF - Guiana Francese 1
GL - Groenlandia 1
GN - Guinea 1
GT - Guatemala 1
KN - Saint Kitts e Nevis 1
KZ - Kazakistan 1
LV - Lettonia 1
LY - Libia 1
MM - Myanmar 1
NO - Norvegia 1
OM - Oman 1
QA - Qatar 1
RS - Serbia 1
Totale 18.779
Salva come PNG Salva come JPEG
Città #
Singapore 1.166
Southend 1.116
Ashburn 613
Fairfield 567
Chandler 559
Ho Chi Minh City 482
Santa Clara 415
Hanoi 412
San Jose 356
Hong Kong 335
Jacksonville 302
Dong Ket 256
Princeton 233
Wilmington 230
Woodbridge 218
Ann Arbor 216
Beijing 215
Hefei 214
Houston 205
Council Bluffs 203
Dublin 191
Seattle 180
Boardman 168
Cambridge 153
Lauterbourg 116
Nanjing 106
Westminster 104
Los Angeles 103
Padova 101
Tokyo 95
Abidjan 92
New York 78
Seoul 78
Da Nang 76
Haiphong 76
Berlin 71
Buffalo 69
Milan 68
Helsinki 67
Bern 63
Saint Petersburg 60
Lomé 59
Medford 58
Bologna 57
Dallas 52
Jinan 47
Hebei 43
Mülheim 43
Shenyang 42
Changsha 39
Nanchang 37
Amman 36
Dearborn 36
Shanghai 35
Guangzhou 34
Mahé 33
San Diego 32
Hải Dương 31
São Paulo 31
Abeokuta 29
Frankfurt am Main 29
Munich 29
Thái Nguyên 29
Turin 29
Biên Hòa 28
Brussels 28
Can Tho 27
Quận Bình Thạnh 26
Sofia 26
Tianjin 25
Falkenstein 23
Florence 23
Des Moines 22
Hangzhou 22
London 22
Mountain View 22
Redondo Beach 22
Verona 22
Bắc Ninh 20
Ha Long 20
The Dalles 19
Chicago 18
Jiaxing 18
Redwood City 18
Brooklyn 17
Kunming 17
Norwalk 17
Bengaluru 16
Ninh Bình 16
Orem 16
Wuhan 16
Falls Church 15
Phoenix 15
Zhengzhou 15
Lanzhou 14
Vinh 14
Atlanta 13
Chengdu 13
Haikou 13
Pune 13
Totale 12.009
Salva come PNG Salva come JPEG
Nome #
G-CSF in Peg-IFN induced neutropenia in liver transplanted patients with HCV recurrence 617
G-CSF administration is not related to PEG-IFN alfa-213 treatment duration nor response in liver transplanted patients with HCV recurrence 522
Two cases of severe autoimmune manifestations following virological response to peginterferon alpha- 2b + ribavirin in liver transplanted patients with recurrence of chronic hepatitis C 343
Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation 333
A new model for portal protein profile analysis in course of ileal intraluminal bile acid infusion using an in situ perfused rat intestine. 306
A statistical model predicting high hepatocyte proliferation index and the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis 279
13C-urea breath test to assess Helicobacter pylori bacterial load. 264
Clinical trial: modulation of human placental multidrug resistance proteins in cholestasis of pregnancy by ursodeoxycholic acid. 258
G-CSF administration is not related to Peg-IFN alfa-2b treatment duration nor response in liver transplanted patients with HCV recurrence. 246
Isolation of stem cell populations with trophic and immunoregulatory functions from human intestinal tissues: potential for cell therapy in inflammatory bowel disease. 243
A RETROSPECTIVE STUDY ON INTRAHEPATIC CHOLESTASIS OF PREGNANCY: MARKERS OF PREMATURE DELIVERY 239
Intestinal epithelial cells in inflammatory bowel diseases 229
Correlazione materno-fetale degli acidi biliari in corso di colestasi gravidica 222
Higher doses of peginterferon alpha-2b administered twice weekly improve sustained virological response in difficult-to-treat patients with chronic hepatitis C: results of a pilot randomized study 218
Clinical efficacy and effectiveness of ursodeoxycholic acid in cholestatic liver diseases. 216
Generation of a novel antibody probe to the Apical Sodium-Dependent Bile Acid Transporter that inhibits ileal bile acid absorption 213
A new oral formulation for the release of sodium butyrate in the ileo-cecal region and colon 209
A new iron free treatment with oral fish cartilage polysaccharide for iron deficiency chronic anemia in inflammatory bowel diseases: a pilot study 208
Long term follow-up and outcome of liver transplantation for alcoholic liver disease: a single center case-control study 207
Reactivation of Crohn's disease after pandemic aH1N1 and seasonal flu vaccinations. 203
Interferon plus ribavirin and interferon alone in preventing hepatocellular carcinoma: a prospective study on patients with HCV related cirrhosis. 203
High thymidylate synthase expression in colorectal cancer with microsatellite instability: implications for chemotherapeutic strategies. 201
Pilot study: the use of sulfasalazine for the treatment of acute pouchitis. 200
Chemiluminescence quantitative immunohistochemical determination of MRP2 in liver biopsies. 196
Infezioni da Helicobacter Pylori e sintomi da reflusso gastro-esofageo nelle donne in gravidanza 193
Ribavirin for chronic hepatitis C: And the mystery goes on. 193
Inflammatory bowel disease: Moving toward a stem cell-based therapy 189
Systemic fungemia and hepatic localizations of Fusarium solani in a liver transplanted patient: An emerging fungal agent. 183
HIGH FREE AND GLYCOCONJUGATED AND LOW TAUROCONJUGATED BA LEVELS IN SERUM ARE THE MIRROR OF INTESTINAL EVENTS AND HEPATIC UPTAKE 181
Mathematical model predicting high hepatocyte proliferation index and risk of HCC in patients with HCV related cirrhosis: a proposal for clinical validation 177
Efficacy of ursodeoxycholic acid administration on clinical manifestations of gallstones and gastrointestinal motility 176
Pharmacological modulation of MRP2 in primary biliary cirrhosis 175
Quantitative immunohistochemistry and in situ hybridization with luminescence detection: a new potential diagnostic tool 171
Pharmacokinetics and safety of a new 1200 mg single-dose delayed release mesalazine microgranule formulation 169
Sviluppo di un biosensore luminescente basato su una linea cellulare ricombinante di epatocarcinoma umano (HepG2) per la determinazione dell’attività di acidi biliarinaturali e sintetici 167
Regolazione dei trasportatori placentari degli acidi biliari MRP2, MRP3, MRP4 da parte dell’acido ursodesossicolico in corso di colestasi gravidica 167
Superior efficacy of twice a week administration of peginterferon alpha-2b plus ribavirin in obtaining SVR in HCV genotype 1 166
The foetal-maternal circulation of bile acids and bilirubin: effects of cholestasis and UDCA administration. 166
Proton pump inhibitors in cirrhosis: tradition or evidence based practice? 166
FXR activity modulation by bile acids and analogs assessed with a recombinant HepG2 cell-based luciferase assay. 165
Glucosamine oral bioavailability and plasma pharmacokinetics after increasing doses of crystalline glucosamine sulfate in man 165
Quantitative immunohistochemistry and in situ hybridization with luminescence detection: a new potential diagnostic tool 164
CMV infection and biliary tract complications are related with a poor outcome of liver transplantation for HCV-related cirrhosis 164
Incidence of gallstone disease in Italy: Results from a multicenter, population-based Italian study (the MICOL project). 164
Serum protein profiling in patients with inflammatory bowel diseases using selective solid-phase bulk extraction, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and chemometric data analysis 163
Gastro-oesophageal reflux symptoms, oesophagitis and Barrett's oesophagus in the general population: the Loiano-Monghidoro study. 162
Development and validation of a HPLC-ESI-MS/MS method for the determination of 5-aminosalicylic acid and its major metabolite N-acetyl-5-aminosalicylic acid in human plasma. 161
Quantitative immunohistochemistry and in situ hybridization imaging procedures with luminescence detection: a new potential diagnostic tool 160
Alimentazione e prevenzione: la salute vien mangiando 160
Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER Study. 159
Mathematical model predicting high hepatocyte proliferation index and risk of HCC in patients with HCV related cirrhosis: a proposal for clinical validation 159
The foetal-maternal circulation of bile acids and bilirubin: effects of cholestasis and UDCA administration. 156
MRP2 is upregulated by UDCA in cholestasis of pregnancy. 156
Hepatic steatosis in obese patients: clinical aspects and prognostic significance. 153
MALDI-TOF MS protein profiling using selective extraction with derivatized cellulose and chemometric analysis: from hepatitis C to hepatocellular carcinoma 152
Serum TUDCA/UDCA concentration profiles after TUDCA oral load: A new test for intestinal transit time and bacteria overgrowth evaluation 151
Effects of UDCA on the foetus-maternal circulation of bilirubin in cholestasis of pregnancy 151
Management of hepatic encephalopathy: focus on antibiotic therapy 151
Safety of interferon beta treatment for chronic HCV hepatitis. 150
Reduced biliary sterol output with no change in total faecal excretion in mice expressing a human apolipoprotein A-I variant 150
SELECTIVE SOLID PHASE EXTRACTION FOR DIRECT MALDI-TOF MS PROFILING OF SERUM PROTEINS 147
UDCA UP-REGULATES HUMAN PLACENTAL BCRP EXPRESSION: PRELIMINARY RESULTS 146
Hepatocellular carcinoma prevention: a worldwide emergence between the opulence of developed countries and the economic constraints of developing nations 145
Salivary TUDCA concentration profiles after TUDCA oral load: a non-invasive test for intestinal transit time evaluation 143
Hypertransaminasemia and pregnancy outcome. 143
Reflux symptoms and Helicobacter pylori in pregnancy 140
Placental MRP2 is upregulated by UDCA in cholestasis of pregnancy. 139
ESWL for difficult bile duct stones: a 15-year single centre experience. 139
UDCA UP-REGULATES HUMAN PLACENTAL OATP-A EXPRESSION IN INTRAHEPATIC CHOLESTASIS OF PREGNANCY 139
Natural history of gallstone disease: Expectant management or active treatment? Results from a population-based cohort study 134
Nuovo metodo per l’arricchimento ed il controllo del processo differenziativo di cellule staminali umane 132
RIBAVIRIN PRIMING ENHANCES EFFICACY OF CHRONIC HEPATITIS C RE-TREATMENT IN PATIENTS WHO HAD NOT RESPONDED TO PREVIOUS COMBINATION THERAPY 131
Genetic polymorphisms of PPAR-alpha: allele frequency in gallstone patients. 130
Effects of UDCA on the foetus-maternal circulation of bilirubin in cholestasis of pregnancy 128
Effects of UDCA on the foetus-maternal circulation of bilirubin in cholestasis of pregnancy 128
Selective solid phase extraction for direct MALDI-TOF MS profiling of serum proteins 128
Modulation of placental bilirubin and bile acids transporters during cholestasis of pregnancy. 127
New tools to monitor stem cells enrichment and differentiation processes by Field-Flow Fractionation 125
Is it possible to predict the clinical course of gallstone disease? Usefulness of gallbladder motility evaluation in a clinical setting 123
Enhanced response to peginterferon-alpha-2a based triple therapy in previously non-responsive chronic hepatitis C: Final results of PRETTY study. 122
Quantitative immunohistochemistry and in situ hybridization imaging procedures with luminescence detection: a new potential diagnostic tool 122
Effects of cholesterol 7alpha-hydroxylase promoter polymorphisms on basal promoter activity and feedback regulation of bile acid synthesis 122
SELECTIVE SOLID PHASE EXTRACTION FOR DIRECT MALDI-TOF MS PROFILING OF SERUM PROTEINS 120
Intestinal microflora and motility in gallstones before and after cholecystectomy: any role for gallstone pathogenesis? 119
Liver transplantation for cholestatic liver diseases: a single center experience 119
Malattia litiasica. 118
Ursodeoxycholic acid improves gastrointestinal motility defects in gallstone patients 117
Effect of chronic administration of ursodeoxycholic acid on gallbladder and gastro-intestinal motility in gallstone patients and healthy controls 114
Efficacy of long term cyclic administration of the poorly absorbed antibiotic Rifaximin in symptomatic, uncomplicated colonic diverticular disease 113
Treatment of acute hepatitis B with high dose lamivudine 110
Measurement of hepatic functional mass by means of 13C-methacetin and 13C-phenylalanine breath tests in chronic liver disease: comparison with Child-Pugh score and serum bile acid levels 110
Efficacy of ursodeoxycholic acid in association with α-interferon for chronic hepatitis C in α-interferon non-responder patients 110
Safety of interferon β treatment for chronic HCV hepatitis 108
Bile acid active and passive ileal transport in the rabbit: effect of luminal stirring 105
Cholic acid metabolism in human fecal cultures during diet supplementation with Lactobacillus rhamnosus GG 105
Metabolic, nutritional and immunological parameters in healthy volunteers after inulin and saccharose feeding 103
Prevalence of different PPAR-alpha gene polymorphisms and haplotypes in gallstone patients. Dig Liv Dis 2005;Vol. 37 Suppl.1:S36. 103
Eradicazione dell'infezione da helicobacter pylori 103
Systemic lupus erythematosus following virological response to peginterferon alfa-2b in a transplanted patient with chronic hepatitis C recurrence 103
Prospective evaluation of aberrant p16 methylation in serum of patients before and after therapy for localized HCC. 103
Totale 17.246
Salva come PNG Salva come JPEG
Categoria #
all - tutte 50.980
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 50.980
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.994 0 97 130 165 167 125 29 103 117 149 577 335
2022/20232.241 259 323 125 266 149 165 62 107 385 51 215 134
2023/2024542 22 87 38 85 56 104 24 26 30 37 12 21
2024/20252.408 70 435 200 151 522 135 119 68 31 154 56 467
2025/20266.100 1.120 511 500 345 702 334 494 140 1.093 432 216 213
2026/2027274 89 185 0 0 0 0 0 0 0 0 0 0
Totale 19.030